Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
Mayo Clinic, Jacksonville, Florida Biogenix Molecular, Miami, Florida The University of Chicago, Chicago, Illinois University of Iowa, Iowa City, Iowa University of Kentucky, Lexington, Kentucky Johns Hopkins, Baltimore, Maryland Barbara Ann Karmanos Cancer Institute, Detroit, Michigan BAMF Health, Grand Rapids, Michigan Michigan Health Professionals, Troy, Michigan Mayo Clinic, Rochester, Minnesota Washington University, St Louis, Missouri Nebraska Cancer Specialists, Omaha, Nebraska University of North Carolina, Chapel Hill, North Carolina Ohio State University, Columbus, Ohio Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Virginia Cancer Specialists, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington